Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Development and validation of an LC-MS/MS method to quantify the bromodomain and extra-terminal (BET) inhibitor JQ1 in mouse plasma and brain microdialysate: Application to cerebral microdialysis study.

Tytuł:
Development and validation of an LC-MS/MS method to quantify the bromodomain and extra-terminal (BET) inhibitor JQ1 in mouse plasma and brain microdialysate: Application to cerebral microdialysis study.
Autorzy:
Nair S; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Davis A; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Campagne O; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Schuetz JD; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA.
Stewart CF; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN, USA. Electronic address: .
Źródło:
Journal of pharmaceutical and biomedical analysis [J Pharm Biomed Anal] 2021 Sep 10; Vol. 204, pp. 114274. Date of Electronic Publication: 2021 Jul 21.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Publication: <2006->: London : Elsevier Science
Original Publication: Oxford ; New York : Pergamon Press, c1983-
MeSH Terms:
Solid Phase Extraction*
Tandem Mass Spectrometry*
Animals ; Brain ; Chromatography, Liquid ; Mice ; Microdialysis ; Reproducibility of Results
References:
Biomed Chromatogr. 2020 Mar;34(3):e4758. (PMID: 31758580)
Clin Cancer Res. 2011 Jan 1;17(1):89-99. (PMID: 21088257)
Nat Rev Dis Primers. 2019 Feb 14;5(1):11. (PMID: 30765705)
Eur J Pharm Sci. 2020 Jan 15;142:105106. (PMID: 31669383)
Nature. 2010 Dec 23;468(7327):1067-73. (PMID: 20871596)
Cell. 2012 Aug 17;150(4):673-84. (PMID: 22901802)
Nature. 2019 Aug;572(7767):74-79. (PMID: 31341285)
Eur J Pharm Sci. 2014 Jun 16;57:41-7. (PMID: 24269626)
Anal Chem. 2003 Jul 1;75(13):3019-30. (PMID: 12964746)
Grant Information:
P30 CA021765 United States CA NCI NIH HHS; R01 CA194057 United States CA NCI NIH HHS
Contributed Indexing:
Keywords: BET inhibitor; Cerebral microdialysis; JQ1; LC–MS/MS; Pharmacokinetics; Solid phase extraction
Entry Date(s):
Date Created: 20210726 Date Completed: 20210824 Latest Revision: 20220911
Update Code:
20240105
PubMed Central ID:
PMC8384680
DOI:
10.1016/j.jpba.2021.114274
PMID:
34311284
Czasopismo naukowe
JQ1, is a cell-permeable small-molecule inhibitor of bromodomain and extra-terminal protein (BET) function with reportedly good CNS penetration, however, unbound and pharmacologically active CNS JQ1 exposures have not been characterized. Additionally, no quantitative bioanalytical methods for JQ1 have been described in the literature to support the CNS penetration studies. In the present article, we discuss the development and validation of a sensitive and reliable liquid chromatography-tandem mass spectrometry (LC-MS/MS) quantitative methods to determine JQ1 in mouse plasma and brain microdialysate. JQ1 and the internal standard, dabrafenib (ISTD), were extracted from plasma and microdialysate samples using a simple solid phase extraction protocol performed on an Oasis HLB μElution plate. Chromatographic separation of JQ1 and ISTD was achieved on a reversed phase C 12 analytical column with gradient elution profile of mobile phases (MP A: water containing 0.1 % formic acid and MP B: acetonitrile containing 0.1 % formic acid) at a flow rate of 0.6 mL/min. The mass spectrometric detection was performed in the positive MRM ion mode by monitoring the transitions 457.40 > 341.30 (JQ1) and 520.40 > 307.20 (ISTD). The calibration curves demonstrated good linearities over the concentration range of 5-1000 ng/mL for the mouse plasma method (r 2 ≥ 0.99) and 0.5-500 ng/mL for the microdialysate method (r 2 ≥ 0.99). The experimental limit of quantification obtained was 5 and 0.5 ng/mL for the mouse plasma and microdialysate method, respectively, with the coefficient of variation less than 10 % for the analyte peak area. All the other validation parameters, including intra-and inter-day accuracy and precision, matrix effect, selectivity, carryover effect, and stability, were within the USFDA bioanalytical guidelines acceptance limits. The LC-MS/MS method was successfully applied to a mouse pharmacokinetic and cerebral microdialysis study to characterize the unbound JQ1 exposure in brain extracellular fluid and plasma.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2021 Elsevier B.V. All rights reserved.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies